This is a prospective, non-interventional, open label, multi center, post marketing surveillance study designed to assess the safety, tolerability and efficacy of Linagliptin among Filipino patients with type 2 Diabetes Mellitus (DM) within the study duration of 24 weeks.
Study Type
OBSERVATIONAL
Enrollment
678
tablet
Frequency of Adverse Events and Serious Adverse Events
Frequency of adverse events and serious adverse events in an actual clinical setting, including hypoglycemic events.
Time frame: Week 24
Change From Baseline to Week 24 of HbA1c
Change from baseline to week 24 of glycosylated hemoglobin (HbA1c)
Time frame: Baseline and 24 weeks
Change From Baseline to Week 24 of Fasting Blood Sugar
Change from baseline to week 24 of fasting blood sugar
Time frame: Baseline and 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Boehringer Ingelheim Investigational Site 43
Agoo, La Union, Philippines
Boehringer Ingelheim Investigational Site 40
Angeles City, Pampanga, Philippines
Boehringer Ingelheim Investigational Site 31
Angono, Rizal, Philippines
Boehringer Ingelheim Investigational Site 32
Antipolo, Rizal, Philippines
Boehringer Ingelheim Investigational Site 27
Aparri, Cagayan, Philippines
Boehringer Ingelheim Investigational Site 4
Batangas, Philippines
Boehringer Ingelheim Investigational Site 48
Butuan City, Agusan Del Norte, Philippines
Boehringer Ingelheim Investigational Site 12
Cabanatuan, Nueva Ecija, Philippines
Boehringer Ingelheim Investigational Site 23
Cagayan de Oro, Philippines
Boehringer Ingelheim Investigational Site 3
Caloocan, Philippines
...and 41 more locations